Professor, Internal Medicine, UC, Davis School of Medicine
Hematology
Dr. Carol M. Richman, MD
|
|
Give Review
Carol M. Richman practices Hematology. She attended Albert Einstein College of Medicine of Yeshiva University. She received 1 awards: "CMS Meaningful Use Stage 1 Certification". Carol Richman is a published physician. She has 36 papers published. The most current publication "Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol." She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
- Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to in...
- Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
- Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N...
- Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.
- Purification and characterization of granulocytic progenitor cells (CFU-C) from human peripheral blood using immunologic surface markers.
- Peripheral blood stem cell transplantation: impact on procedure load and workload in an apheresis unit.
- Cryopreserved autologous marrow infusion following high dose cancer chemotherapy.
- Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation.
- Correlation of in vitro culture pattern and Q-banded karyotype in acute nonlymphocytic leukemia.
- The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia.
- Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.
- Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
- Enhancement of clinical radioimmunotherapy for cancer and the role of cytokines.
- Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
- Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
- Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect wi...
- An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
- Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
- Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation.
- Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma.
- Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6.
- Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
- Strategies for developing effective radioimmunotherapy for solid tumors.
- Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
- Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
- Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.
- Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
- Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
- Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-...
- Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
- Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
- Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
- Acute myocardial infarction in hemoglobin SC disease.
Doctors Specialties
- Internal Medicine
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Boston University Medical Center -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
University of California, Davis Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Brigitte L. Berry, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark J. Labriola, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priyasheelta Nand, MD |
|
|
Dr. Philip W. Poor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer L. Hefner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mrinal P. Dutia, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Shahzad A. Siddique, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sivakumar Y. Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derick H. Lau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Jonas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald M. Wisdom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert T. O'Donnell, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Stacy D. D'Andre, MD
This Doctor is OpenDoctor Recommended.
|